• LevelJump will issue up to 16,666,667 units at $0.15 per unit for gross proceeds of up to $2,500,000
  • Net proceeds from the financing will be used towards acquisitions and for general working capital purposes
  • The offering is expected to close in late January
  • Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology
  • Shares in Leveljump Healthcare Corp. (JUMP) are down 4.76 per cent on the day, trading at C$0.10 per share at 12:30 pm EST

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement financing for gross proceeds of up to $2,500,000.

The company will issue up to 16,666,667 units at $0.15 per unit. Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share of Leveljump at an exercise price of $0.20 with an expiry date of January 31, 2024.

The net proceeds from the financing will be used towards acquisitions and for general working capital purposes.

The offering is expected to close in late January.

Securities issued will be subject to a four-month hold period in accordance with applicable securities laws.

Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The company provides radiology solutions for hospitals, emergency rooms, and private clinics.

Shares in Leveljump Healthcare Corp. (JUMP) are down 4.76 per cent on the day, trading at C$0.10 per share at 12:30 pm EST.

More From The Market Online

MindBio debuts AI speech tool to spot substance abuse

MindBio Therapeutics (CSE:MBIO) develops the world's first AI prediction tool for drug and alcohol intoxication using voice analysis.

An immunotherapy value play advancing the fight against bladder cancer

An in-depth look at BioVaxys Technology (CSE:BIOV), a micro-cap stock combining a promising drug pipeline with irrational investor pessimism.
The Market Online Video

Developing a neurosciences platform with potential applications across several indications

In this Capital Compass episode, Marvel Biosciences outlines progress on MB-204, its neuroscience platform targeting autism, Rett syndrome, Fragile X, and Alzheimer’s disease ahead…